Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.
Company Details
- Employees
- 59
- Address
- Space But For Telling The Story Of How It Came To Be. Check Out John Maraganore In Their Feature Below And Learn More About Us At Citytx.com.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.citytx.com
- Keywords
- in drug development..
City Therapeutics Questions
City Therapeutics's website is https://www.citytx.com
City Therapeutics's LinkedIn profile is https://www.linkedin.com/company/city-therapeutics
City Therapeutics has
59 employees.
View email and phone details for 59
employees at City Therapeutics.
City Therapeutics's industry is
Biotechnology Research
City Therapeutics's top competitors are
Triveni Bio,
Judo Bio,
Seaport Therapeutics,
Avencell,
A2 Biotherapeutics, Inc.,
Terray Therapeutics,
Atalanta Therapeutics,
Kailera Therapeutics,
Aktis Oncology,
Aspect Biosystems.
City Therapeutics's categories are Biotechnology Research
